Substance P

DRUG6 trials

Sponsors

Northwestern University, Vanilloid Genetics Inc., Vanderbilt University Medical Center, GlaxoSmithKline, Danish Headache Center

Conditions

Diabetes Mellitus, Type 1Healthy Volunteers OnlyHypertensionMigraineSeasonal Allergic RhinitisSkin Diseases

Phase 1

Reduction of IgE Antibody in Human Allergic Subjects

CompletedNCT01280149

Northwestern UniversitySeasonal Allergic Rhinitis

Start: 2011-01-31End: 2017-06-20Updated: 2018-08-21

Neuropeptide Therapy of Recent Onset Type 1 Diabetes

Vanilloid Genetics Inc.Diabetes Mellitus, Type 1

Start: 2016-05-31End: 2022-12-31Target: 12Updated: 2020-05-21

Phase 4

Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1

TerminatedNCT03738878

Vanderbilt University Medical CenterHypertension

Start: 2018-11-15End: 2024-12-01Updated: 2025-08-03

Unknown Phase

Substance P Challenge in Healthy Participants

CompletedNCT04676763

GlaxoSmithKlineSkin Diseases

Start: 2021-03-02End: 2021-07-21Updated: 2025-01-20

Effects of Substance P on Headache Induction in Healthy Individuals

Not yet recruitingNCT06632080

Danish Headache CenterHealthy Volunteers Only

Start: 2024-10-14End: 2025-12-31Target: 21Updated: 2024-10-15

Substance P-Induced Migraine Attacks Without Aura

RecruitingNCT06959004

Danish Headache CenterMigraine

Start: 2025-05-13End: 2026-12-01Target: 21Updated: 2025-06-05

Related Papers

Effects of substance P on headache induction and arterial dilation in healthy adults

Cephalalgia2025-05-016 citations